5-({4-[2-aminoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione | 119670-22-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-({4-[2-aminoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
• 英文别名: 5-[4-(2-Aminoethoxy)Benzyl]-2,4-Thiazolidinedione；5-[4-(2-Aminoethoxy)Benzyl]-2,4-Thiazolidine-dione；5-[[4-(2-aminoethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 119670-22-3
• 化学式: C₁₂H₁₄N₂O₃S
• 分子量: 266.321
• InChiKey: TYDGXJOMVWMDOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  9-芴甲基-N-琥珀酰亚胺基碳酸酯 、 5-({4-[2-aminoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione 以 乙腈 为溶剂， 以90%的产率得到
  参考文献：
  名称：

  Solid-phase synthesis of hybrid thiazolidinedione-fatty acid PPARγ ligands

  摘要：

  A library of thiazolidinedione-fatty acid hybrid molecules was designed to probe the relationship between natural and synthetic PPAR ligands. Solid-phase synthesis of the library led to the identification of several high affinity PPAR gamma ligands. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10017-8
• 作为产物：
  描述：

  5-[4-(2-aminoethoxy)benzyl]-1,3-thiazolidine-2,4-dione hydrochloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 5-({4-[2-aminoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
  参考文献：
  名称：

  1,2-dithiolane derivatives

  摘要：

  这项发明提供了新的噻唑烷二酮衍生物和新的芳基乙酸衍生物。这些化合物对治疗心血管疾病、某些内分泌疾病、某些炎症性疾病、某些恶性和非恶性增殖性疾病、某些神经精神障碍、某些病毒性疾病以及与这些病毒感染相关的疾病是有用的。

  公开号：

  US06353011B1

文献信息

• Novel thiazolidinediones
  申请人：Beecham Group p.l.c.

  公开号：US04918091A1

  公开（公告）日：1990-04-17

  A compound of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, wherein: R represents hydrogen or alkyl; R.sup.1 represents an alkyl group or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A represents a benzene ring having in total up to five substituents; X represents oxygen, sulphur or a moiety NR.sup.4 wherein R.sup.4 represents hydrogen or alkyl; and n represents an integer in the range of from 2 to 6; a process for preparing such a compound, a composition containing such a compound and the use of the compound and composition in medicine.

  一种具有以下式（I）的化合物：##STR1##或其互变异构体，或其药学上可接受的盐，其中：R代表氢或烷基；R.sup.1代表烷基或取代或未取代的芳基；R.sup.2和R.sup.3各自代表氢，或R.sup.2和R.sup.3一起代表键；A代表具有总共多达五个取代基的苯环；X代表氧、硫或一个基团NR.sup.4，其中R.sup.4代表氢或烷基；n代表范围在2到6之间的整数；一种制备这种化合物的方法，含有这种化合物的组合物以及该化合物和组合物在医学中的用途。
• Indole derivatives
  申请人：Zisapel Nava

  公开号：US20050159463A1

  公开（公告）日：2005-07-21

  The invention relates to 1-(R 1 )-2-(R 2 )-3-(Y-X-NH-A- or Z-A-)-4,5,6,7-R) 0-4 -indoles, and their acid addition salts where the compounds are basic, wherein A is C 1-4 alkylene, X is >CH 2 , >C=O or >C=S, and the other symbols have various defined values, and to pharmaceutical, skin-protective and cosmetic compositions which comprise them.

  本发明涉及1-(R1)-2-(R2)-3-(Y-X-NH-A-或Z-A-)-4,5,6,7-R)0-4-吲哚及其酸加成盐，其中化合物是碱性的，其中A为C1-4烷基，X为>CH2，>C=O或>C=S，其他符号具有各自定义的值，并涉及包含它们的制药、皮肤保护和化妆品组合物。
• Novel compounds
  申请人：BEECHAM GROUP PLC

  公开号：EP0295828A1

  公开（公告）日：1988-12-21

  A compound of formula (I): or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, wherein: R represents hydrogen or alkyl; R1 represents an alkyl group or a substituted or unsubstituted aryl group; R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond; A represents a benzene ring having in total up to five substituents; X represents oxygen, sulphur or a moiety NR4 wherein R4 represents hydrogen or alkyl; and n represents an integer in the range of from 2 to 6; a process for preparing such a compound, a composition containing such a compound and the use of the compound and composition in medicine.

  式(I)化合物 或其同分异构形式，或其药学上可接受的盐，其中 R 代表氢或烷基 R1 代表烷基或取代或未取代的芳基； R2 和 R3 各自代表氢，或 R2 和 R3 共同代表键； A 代表一个苯环，其上总共有最多五个取代基； X 代表氧、硫或分子 NR4，其中 R4 代表氢或烷基；以及 n 代表 2 至 6 之间的整数；制备这种化合物的工艺、含有这种化合物的组合物以及这种化合物和组合物在医药中的用途。
• [[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents
  作者：Barrie C. C. Cantello、Michael A. Cawthorne、Graham P. Cottam、Peter T. Duff、David Haigh、Richard M. Hindley、Carolyn A. Lister、Stephen A. Smith、Peter L. Thurlby

  DOI：10.1021/jm00049a017

  日期：1994.11

  A series of [(ureidoethoxy)benzyl]-2,4-thiazolidinediones and [[(heterocyclylamino)alkoxy]-benzyl]-2,4-thiazolidinediones was synthesized from the corresponding aldehydes. Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045). The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies. Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 Bl/6 ob/ob mice. From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.
• INDOLE DERIVATIVES
  申请人：NEURIM PHARMACEUTICALS (1991) LIMITED

  公开号：EP1189583B1

  公开（公告）日：2005-07-20